

Haematologica  
HAEMATOL/2015/128371  
Version 2

Precision medicine in diffuse large B cell lymphoma: Hitting the target

Disclosures: J.S. Vermaat has nothing to declare. S.T. Pals has nothing to declare. A. Younes has received research funding and/or honorarium from Celgene, Novartis, Seattle Genetics, Takeda, Janssen, Infinity, Gilead, Curis, and Constellation. M. Dreyling has received institutional research funding and/or honoraria from Bayer, Celgene, Gilead, Janssen, Mundipharma, Pfizer and Roche. M. Federico has received research support and/or honoraria from Celgene, Mundipharma, Millennium/Takeda, Roche and Janssen. I. Aurer has received research support and honoraria from Roche, Celgene, Millennium/Takeda, Johnson&Johnson and Amgen. M.J. Kersten has received research support and/or honoraria from Celgene, Roche, Mundipharma, Millennium/Takeda, Sanofi, Gilead, Janssen and Amgen.

Contributions: All authors wrote the manuscript.